Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8NFA0
UPID:
UBP32_HUMAN
Alternative names:
Deubiquitinating enzyme 32; Renal carcinoma antigen NY-REN-60; Ubiquitin thioesterase 32; Ubiquitin-specific-processing protease 32
Alternative UPACC:
Q8NFA0; Q7Z5T3; Q9BX85; Q9Y591
Background:
Ubiquitin carboxyl-terminal hydrolase 32, also known as Deubiquitinating enzyme 32, plays a crucial role in cellular processes by removing conjugated ubiquitin from target proteins such as RAB7A and LAMTOR1. This action is pivotal for the positive regulation of the mTORC1 signaling pathway, enhancing the association between LAMTOR1 and the lysosomal V-ATPase complex, thereby activating the mTORC1 complex.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase 32 could open doors to potential therapeutic strategies.